Targeting Interleukin-8–Mediated Cellular Crosstalk Reverses Hypertrophic Cardiomyopathy and Cardiac Fibrosis in Noonan Syndrome
Open Access
- 16 April 2026
- journal article
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (14) , 1339-1359
Abstract
BACKGROUND: Genetic variants in components or regulators of the RAS-MAPK signaling pathway are causative for severe and early-onset hypertrophic cardiomyopathy (HCM) in patients with Noonan syndrome (NS). Despite paracrine communication being considered to play a pivotal role in the etiology of cardiomyopathies, there is a paucity of knowledge about the underlying pathomechanism that leads to the development of hypertrophic cardiomyopathy and cardiac fibrosis in NS. METHODS: To dissect the impact of noncardiomyocytes in the development of NS, we employed two-dimensional and three-dimensional human induced pluripotent stem cell models of LZTR1 deficiency alongside induced pluripotent stem cells derived from patients with NS with pathogenic variants in key RAS-MAPK genes and analyzed these cells and tissues at the molecular, cellular, and functional levels. RESULTS: Our findings revealed that cytokine-mediated cellular crosstalk between cardiac fibroblasts and cardiomyocytes, predominantly activated in the disease state, serves as a primary driver of the disease. Cardiac fibroblast–specific IL-8 (interleukin-8) secretion induced fibrosis-related signatures, tissue stiffness, cardiomyocyte hypertrophy, and hypercontractility, identifying dysregulated IL-8 as a heart-autonomous signaling molecule independent of inflammation and immune cell involvement. Inhibition of IL-8–CXCR1 signaling by reparixin reversed the pathological effects in cardiac fibroblasts and cardiomyocytes. CONCLUSIONS: These data provide evidence that targeting aberrant IL-8–CXCR1 signaling may be an effective therapeutic option for patients with NS-associated hypertrophic cardiomyopathy.Keywords
This publication has 56 references indexed in Scilit:
- Natural History and Outcomes in Paediatric RASopathy-Associated Hypertrophic CardiomyopathyESC Heart Failure, 2024
- The molecular genetics of RASopathies: An update on novel disease genes and new disordersAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2022
- Genotype‐cardiac phenotype correlations in a large single‐center cohort of patients affected by RASopathies: Clinical implications and literature reviewAmerican Journal of Medical Genetics Part A, 2021
- Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosisEuropean Journal of Heart Failure, 2021
- A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)Breast Cancer Research and Treatment, 2021
- Efficient generation of osteoclasts from human induced pluripotent stem cells and functional investigations of lethal CLCN7-related osteopetrosisJournal of Bone and Mineral Research, 2020
- Congenital heart defects in Noonan syndrome: Diagnosis, management, and treatmentAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2020
- Cell Detection with Star-Convex Polygons2018
- Role of cytokines and inflammation in heart function during health and diseaseHeart Failure Reviews, 2018
- Increased proteome coverage by combining PAGE and peptide isoelectric focusing: Comparative study of gel‐based separation approachesProteomics, 2013